Dyve Biosciences
Thousand Oaks
About Dyve Biosciences
Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery. The company is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary science. Dyve’s most advanced asset, DYV-700, is in phase 2 for the treatment of acute gout using a mechanism of action enabled by Dyve’s science. The company has PK data demonstrating injection-like delivery across a broad range of molecules. It was founded in 2014 and is headquartered in Thousand Oaks, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $9.8M
- Last round: Series Unknown (Aug 2020)
- Website: dyvebio.com
- Phone: 805-857-6449
Industries & Categories
Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/dyve-biosciences-137801 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.